Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.
Genetic complexity doesn't worsen outcomes after stem cell transplant in Philadelphia-positive leukemia when using targeted drugs, simplifying transplant decision-making.
This large multicenter EBMT registry study compared transplantation outcomes in 345 Ph+ ALL patients with additional cytogenetic abnormalities versus 169 without, finding no significant difference in major outcomes after TKI-bridged allogeneic SCT. The findings challenge the assumption that ACAs uniformly worsen prognosis in the TKI era and have implications for transplant decision-making in this specific ALL subgroup.
What the study was
- Study design
- Retrospective multicenter cohort study (EBMT registry)
- Population
- Ph+ ALL patients receiving TKI before allogeneic SCT: ACAs (n=345) vs no ACAs (n=169)
- Sample size
- 514
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Bone marrow transplantation
Why it surfaced
Large registry study addressing prognostic significance of additional cytogenetic abnormalities in Ph+ ALL after TKI treatment, with direct implications for transplant candidacy evaluation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.